Recent advances in targeted strategies for triple-negative breast cancer

Journal of Hematology & Oncology

Review

Bin Song¹  Qi Mei²  Kongming Wu²  Ming Yi³  Yuze Wu⁴  Yuheng Yan⁴  Shuangli Zhu⁴ 

[1]Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032, Taiyuan, China

[2]Cancer Center, Shanxi Bethune Hospital, Shanxi Academy of Medical Science, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, 030032, Taiyuan, China

[3]Cancer Center, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China

[4]Department of Breast Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, 310000, Hangzhou, China

[5]Department of Oncology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, 430030, Wuhan, China

关键词: Triple-negative breast cancer;    Molecular subtype;    Targeted therapy;    Immunotherapy;   

DOI  :  10.1186/s13045-023-01497-3

 received in 2023-06-14, accepted in 2023-08-21,  发布年份 2023

来源: Springer

【 摘 要 】

Triple-negative breast cancer (TNBC), a highly aggressive subtype of breast cancer, negatively expresses estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2 (HER2). Although chemotherapy is the main form of treatment for patients with TNBC, the effectiveness of chemotherapy for TNBC is still limited. The search for more effective therapies is urgent. Multiple targeted therapeutic strategies have emerged according to the specific molecules and signaling pathways expressed in TNBC. These include PI3K/AKT/mTOR inhibitors, epidermal growth factor receptor inhibitors, Notch inhibitors, poly ADP-ribose polymerase inhibitors, and antibody–drug conjugates. Moreover, immune checkpoint inhibitors, for example, pembrolizumab, atezolizumab, and durvalumab, are widely explored in the clinic. We summarize recent advances in targeted therapy and immunotherapy in TNBC, with the aim of serving as a reference for the development of individualized treatment of patients with TNBC in the future.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4

Fig. 9

Fig. 1

42490_2023_74_Article_IEq27.gif